Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Company

Torrent Pharmaceuticals

Pharmaceutical intelligence for Torrent Pharmaceuticals with 20 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 11
Catalysts: 1
Assets: 9

Recent signals(11)

StrategyAugust 5, 2026

Torrent's Rosuvastatin Calcium ANDA Receives Approval Status

Torrent's ANDA201619 for Rosuvastatin Calcium has received an approval status (AP) from the FDA.

StrategyJuly 30, 2026

FDA Accepts Lenalidomide ANDA Submission from Torrent

The FDA has accepted the ANDA submission for Lenalidomide from Torrent Pharmaceuticals.

RegulatoryJuly 28, 2026

FDA Submission Overview for Vericiguat by Torrent Pharmaceuticals

Torrent Pharmaceuticals has submitted an original application for Vericiguat (ANDA220221) to the FDA, currently under standard review.

StrategyJuly 26, 2026

FDA Grants AP Status for Lurasidone Hydrochloride ANDA208055

The FDA has granted approval status (AP) for the ANDA208055 application for Lurasidone Hydrochloride submitted by Torrent.

StrategyJuly 26, 2026

FDA Grants AP Status for Lamotrigine ANDA078947 by Torrent Pharmaceuticals

The FDA has granted Abbreviated Approval (AP) status for Torrent Pharmaceuticals' ANDA078947 for Lamotrigine.

RegulatoryJuly 24, 2026

Torrent's Moxifloxacin Hydrochloride ANDA Receives Approval Status

Torrent's ANDA for Moxifloxacin Hydrochloride has received an approval status (AP) from the FDA.

StrategyJuly 24, 2026

Torrent Pharmaceuticals receives AP status for Metformin Hydrochloride ANDA079226

Torrent Pharmaceuticals has received an Abbreviated Approval (AP) for their ANDA079226 for Metformin Hydrochloride.

StrategyJuly 24, 2026

Torrent's Metformin Hydrochloride ANDA090014 Receives AP Status

Torrent's ANDA for Metformin Hydrochloride has received an Abbreviated Approval (AP) status from the FDA.

StrategyJuly 23, 2026

Torrent Pharmaceuticals receives AP status for Metformin Hydrochloride ANDA077711

Torrent Pharmaceuticals has received an Abbreviated Approval (AP) for their ANDA077711 application for Metformin Hydrochloride.

StrategyJuly 5, 2026

Torrent Pharmaceuticals submits ANDA for Vericiguat

Torrent Pharmaceuticals has submitted an Abbreviated New Drug Application (ANDA) for Vericiguat.

CompetitiveJune 10, 2026

Torrent's Lurasidone Hydrochloride ANDA Receives AP Status from FDA

Torrent's ANDA for Lurasidone Hydrochloride has received an Abbreviated Approval (AP) status from the FDA.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity(2)

RegulatoryJuly 28, 2026

FDA Submission Overview for Vericiguat by Torrent Pharmaceuticals

Torrent Pharmaceuticals has submitted an original application for Vericiguat (ANDA220221) to the FDA, currently under standard review.

RegulatoryJuly 24, 2026

Torrent's Moxifloxacin Hydrochloride ANDA Receives Approval Status

Torrent's ANDA for Moxifloxacin Hydrochloride has received an approval status (AP) from the FDA.

Clinical activity

No signals indexed for this entity yet.

Competitive activity(1)

CompetitiveJune 10, 2026

Torrent's Lurasidone Hydrochloride ANDA Receives AP Status from FDA

Torrent's ANDA for Lurasidone Hydrochloride has received an Abbreviated Approval (AP) status from the FDA.

Assets

Lamotrigine →

Lurasidone Hydrochloride →

Metformin Hydrochloride →

Moxifloxacin Hydrochloride →

Regulatory Approval →

Rosuvastatin →

Therapeutic areas

Antiepileptic →

Antipsychotic →

Cardiovascular →

Cardiovascular · Statin →

Diabetes · Oral Hypoglycemic →

Heart Failure →

Infectious Disease →

Infectious Disease · Antibiotic →

Neurology · Antiepileptic →

Oncology · Small Molecule →

Oral Hypoglycemic →

Psychiatry · Antipsychotic →

Small Molecule →

Indications

Infectious Disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.